Jaguar Health is a pharmaceuticals company that develops plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal distress, such as chronic, debilitating diarrhea. Co.'s subsidiary, Napo Pharmaceuticals, Inc. (Napo), develops and commercializes proprietary plant-based human pharmaceuticals. Napo's marketed drug Mytesi (crofelemer 125 mg delayed-release tablets) is an oral botanical drug product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Co.'s Canalevia-CA1 (crofelemer delayed-release tablets) drug is an oral plant-based prescription product to treat chemotherapy-induced diarrhea in dogs. The JAGX YTD return is shown above.
The YTD Return on the JAGX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether JAGX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JAGX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|